Germany Pneumococcal Vaccines Market Size & Share Analysis - Growth, Trends & Forecasts (2025 - 2030)

The Germany Pneumococcal Vaccines Market Report is Segmented by Vaccine Type (Conjugate Vaccine, and Polysaccharide Vaccine), Product Type (Prevnar 13, Synflorix, and Pneumovax23), and Distribution Channel (Distribution Partner Companies, Non-Governmental Organizations, and Government Authorities). The Report Offers the Value (in USD) for the Above Segments.

Germany Pneumococcal Vaccines Market Size & Share Analysis - Growth, Trends & Forecasts (2025 - 2030)

Germany Pneumococcal Vaccines Market Size

Germany Pneumococcal Vaccines Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Market Size (2025) USD 434.77 Million
Market Size (2030) USD 487.13 Million
CAGR (2025 - 2030) 2.30 %
Market Concentration Medium

Major Players

Germany Pneumococcal Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Germany Pneumococcal Vaccines Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Germany Pneumococcal Vaccines Market Analysis

The Germany Pneumococcal Vaccines Market size is estimated at USD 434.77 million in 2025, and is expected to reach USD 487.13 million by 2030, at a CAGR of 2.3% during the forecast period (2025-2030).

Pneumococcal vaccines protect children and adults from serious infections caused by pneumonia. There are two main types of pneumococcal vaccines: pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV). These vaccines contain different types of pneumococcus, which are combined to create doses for vaccinating children and adults. The increasing prevalence of pneumonia, increasing government awareness programs regarding pneumonia immunization, and growing research and development for developing novel vaccines are the major factors contributing to market growth.

The high prevalence of invasive pneumococcal disease (IPD) amongst the geriatric population in the country is projected to drive market growth during the forecast period. For instance, according to an article published in the Epidemiology & Infection Journal in July 2022, invasive pneumococcal disease (IPD) in people aged over 60 is rising in Germany. Thus, the high prevalence of IPD among the elderly population is projected to lead to an increased demand for pneumococcal vaccines by seeking vaccination as a preventive measure among healthcare providers and individuals, thereby boosting market growth in the country.

In addition, the rising geriatric population in the country is also projected to enhance market growth during the forecast period. For instance, according to the article published by the Statistisches Bundesamt (Destatis) in December 2022, the number of people aged 67 years or over in Germany is projected to increase by around 4 million in 2022 to 20.0 million by the end of 2030. Therefore, the surging geriatric population in the country is estimated to drive market growth during the forecast period owing to an increase in demand for pneumococcal vaccines.

Moreover, the increasing government initiatives regarding pneumonia immunization are projected to drive market growth during the forecast period. For instance, in January 2022, the Standing Vaccination Committee (STIKO) vaccination recommendations at the Robert Koch Institute were launched. The STIKO vaccination primary goal was to vaccinate children up to 24 months of age with the pneumococcal conjugate vaccine in Germany to reduce morbidity from invasive pneumococcal diseases (IPD) and resulting consequences such as hospitalization, disability, and death. Thus, the STIKO's recommendation to vaccinate all children up to 24 months of age with the pneumococcal conjugate vaccine is projected to boost vaccination rates among infants and toddlers in Germany significantly.

Therefore, factors such as the high prevalence of IPD amongst the geriatric population in the country and the active participation of government bodies, such as launching standard vaccination programs, are projected to drive market growth during the forecast period.

However, factors such as long duration and high cost of producing pneumococcal vaccines may hinder market growth during the study period.

Germany Pneumococcal Vaccines Industry Overview

The Germany pneumococcal vaccines market is consolidated due to a few large companies dominating the majority of market share, including GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc, and CSL Ltd., among others. Key players are using their existing customer bases in the region to maintain high-quality standards and gain a large market share. These players are investing heavily in advanced products and infrastructure, allowing them to process and analyze a large number of samples efficiently.

Germany Pneumococcal Vaccines Market Leaders

  1. GlaxoSmithKline plc

  2. Pfizer Inc.

  3. Merck & Co., Inc

  4. CSL Ltd.

  5. Sanofi

  6. *Disclaimer: Major Players sorted in no particular order
Germany Pneumococcal Vaccines Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Germany Pneumococcal Vaccines Market News

  • March 2024: The European Commission (EC) granted Pfizer Inc. marketing authorization for its 20-valent pneumococcal conjugate vaccine. In the European Union, including Germany, the vaccine is branded as PREVENAR 20 and is designed to protect infants and children from pneumococcal disease.
  • February 2022: Pfizer Inc. received the European Medicines Agency (EMA) approval for its 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.

Germany Pneumococcal Vaccines Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Government Awareness Programs and Introduction of Novel Pneumococcal Vaccines
    • 4.2.2 Rising Prevalence Of Pneumonia and Surging Targeted Population
  • 4.3 Market Restraints
    • 4.3.1 High Cost and Long Duration of the Production
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value-USD)

  • 5.1 By Vaccine Type
    • 5.1.1 Pneumococcal Conjugate Vaccine
    • 5.1.2 Pneumococcal Polysaccharide Vaccine
  • 5.2 By Product Type
    • 5.2.1 Prevnar 13
    • 5.2.2 Synflorix
    • 5.2.3 Pneumovax23
  • 5.3 By Distribution Channel
    • 5.3.1 Distribution Partner Companies
    • 5.3.2 Non-governmental Organizations
    • 5.3.3 Government Authorities

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline plc
    • 6.1.2 Pfizer Inc.
    • 6.1.3 Merck & Co., Inc
    • 6.1.4 CSL Ltd.
    • 6.1.5 Sanofi
    • 6.1.6 Johnson and Johnson
    • 6.1.7 Novartis AG
    • 6.1.8 Astellas Pharma Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Germany Pneumococcal Vaccines Industry Segmentation

As per the scope of the report, pneumococcal vaccines are immunizations designed to protect against infections caused by the bacterium Streptococcus pneumoniae. This bacterium can lead to serious illnesses, including pneumonia, meningitis, and bloodstream infections. The Germany pneumococcal vaccines market is segmented into vaccine type, product type, and distribution channel. By vaccine type, the market is segment into conjugate vaccine and polysaccharide vaccine. By product type, the market is segmented into Prevnar 13, Synflorix, and Pneumovax23. By distribution channel, the market is segmented into distribution partner companies, non-governmental organizations, and government authorities). The report offers the value (in USD) for the above segments.

By Vaccine Type Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine
By Product Type Prevnar 13
Synflorix
Pneumovax23
By Distribution Channel Distribution Partner Companies
Non-governmental Organizations
Government Authorities
Need A Different Region or Segment?
Customize Now

Germany Pneumococcal Vaccines Market Research FAQs

How big is the Germany Pneumococcal Vaccines Market?

The Germany Pneumococcal Vaccines Market size is expected to reach USD 434.77 million in 2025 and grow at a CAGR of 2.30% to reach USD 487.13 million by 2030.

What is the current Germany Pneumococcal Vaccines Market size?

In 2025, the Germany Pneumococcal Vaccines Market size is expected to reach USD 434.77 million.

Who are the key players in Germany Pneumococcal Vaccines Market?

GlaxoSmithKline plc, Pfizer Inc., Merck & Co., Inc, CSL Ltd. and Sanofi are the major companies operating in the Germany Pneumococcal Vaccines Market.

What years does this Germany Pneumococcal Vaccines Market cover, and what was the market size in 2024?

In 2024, the Germany Pneumococcal Vaccines Market size was estimated at USD 424.77 million. The report covers the Germany Pneumococcal Vaccines Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Germany Pneumococcal Vaccines Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Germany Pneumococcal Vaccines Industry Report

Statistics for the 2025 Germany Pneumococcal Vaccines market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Germany Pneumococcal Vaccines analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.